Compile Data Set for Download or QSAR
Report error Found 188 Enz. Inhib. hit(s) with all data for entry = 10382
TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532051(US11208422, Example 12 | 3-{[2-(4-Chlorophenyl)imi...)
Affinity DataIC50: 1.10nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532241(US11208422, Example 83 | US11208422, Example 82)
Affinity DataIC50: 1.40nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532228(US11208422, Example 88 | US11208422, Example 89 | ...)
Affinity DataIC50: 1.60nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532162(US11208422, Example 14 | 3-{[2-(4-Chlorophenyl)imi...)
Affinity DataIC50: 2.20nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532051(US11208422, Example 12 | 3-{[2-(4-Chlorophenyl)imi...)
Affinity DataIC50: 2.5nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532051(US11208422, Example 12 | 3-{[2-(4-Chlorophenyl)imi...)
Affinity DataIC50: 2.5nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532229(US11208422, Example 91 | US11208422, Example 90 | ...)
Affinity DataIC50: 2.80nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532179(US11208422, Example 38 | US11208422, Example 27)
Affinity DataIC50: 3nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532179(US11208422, Example 38 | US11208422, Example 27)
Affinity DataIC50: 4nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532173(US11208422, Example 32 | US11208422, Example 21)
Affinity DataIC50: 4.10nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532181(US11208422, Example 40 | US11208422, Example 29)
Affinity DataIC50: 4.40nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532162(US11208422, Example 14 | 3-{[2-(4-Chlorophenyl)imi...)
Affinity DataIC50: 4.5nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532229(US11208422, Example 91 | US11208422, Example 90 | ...)
Affinity DataIC50: 4.70nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532232(US11208422, Example 73)
Affinity DataIC50: 5nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532237(US11208422, Example 79 | US11208422, Example 78)
Affinity DataIC50: 5nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532231(US11208422, Example 72)
Affinity DataIC50: 5.10nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532229(US11208422, Example 91 | US11208422, Example 90 | ...)
Affinity DataIC50: 5.5nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532180(US11208422, Example 39 | US11208422, Example 28)
Affinity DataIC50: 5.60nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532178(US11208422, Example 37 | US11208422, Example 26)
Affinity DataIC50: 6.90nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532166([3-{[2-(5-Chloropyridin-2-yl)imidazo[1,2-a]pyridin...)
Affinity DataIC50: 7.30nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532166([3-{[2-(5-Chloropyridin-2-yl)imidazo[1,2-a]pyridin...)
Affinity DataIC50: 7.54nMAssay Description:Xenopus laevis oocytes were selected as described elsewhere by way of illustration [Decher et al., FEBS Lett. 492, 84-89 (2001)]. Subsequently, the o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532239(US11208422, Example 81 | US11208422, Example 80)
Affinity DataIC50: 9.20nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532174(US11208422, Example 25 | US11208422, Example 22)
Affinity DataIC50: 11nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532237(US11208422, Example 79 | US11208422, Example 78)
Affinity DataIC50: 11nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532051(US11208422, Example 12 | 3-{[2-(4-Chlorophenyl)imi...)
Affinity DataIC50: 11.4nMAssay Description:Xenopus laevis oocytes were selected as described elsewhere by way of illustration [Decher et al., FEBS Lett. 492, 84-89 (2001)]. Subsequently, the o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532162(US11208422, Example 14 | 3-{[2-(4-Chlorophenyl)imi...)
Affinity DataIC50: 12nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532180(US11208422, Example 39 | US11208422, Example 28)
Affinity DataIC50: 13nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532169(US11208422, Example 33 | [6-{[2-(4-Chlorophenyl)im...)
Affinity DataIC50: 15nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532256((3-Chloro-6-methoxypyridin-2-yl) [3-{[2-(4-isoprop...)
Affinity DataIC50: 16nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532241(US11208422, Example 83 | US11208422, Example 82)
Affinity DataIC50: 17nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532051(US11208422, Example 12 | 3-{[2-(4-Chlorophenyl)imi...)
Affinity DataIC50: 17.6nMAssay Description:Xenopus laevis oocytes were selected as described elsewhere by way of illustration [Decher et al., FEBS Lett. 492, 84-89 (2001)]. Subsequently, the o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532224(US11208422, Example 66 | US11208422, Example 65)
Affinity DataIC50: 19nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532228(US11208422, Example 88 | US11208422, Example 89 | ...)
Affinity DataIC50: 19nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532162(US11208422, Example 14 | 3-{[2-(4-Chlorophenyl)imi...)
Affinity DataIC50: 20.6nMAssay Description:Xenopus laevis oocytes were selected as described elsewhere by way of illustration [Decher et al., FEBS Lett. 492, 84-89 (2001)]. Subsequently, the o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532175(US11208422, Example 34 | US11208422, Example 23)
Affinity DataIC50: 24nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532176(US11208422, Example 35 | US11208422, Example 24)
Affinity DataIC50: 24nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532243(US11208422, Example 85 | US11208422, Example 84)
Affinity DataIC50: 25nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532245(US11208422, Example 87 | US11208422, Example 86)
Affinity DataIC50: 28nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532181(US11208422, Example 40 | US11208422, Example 29)
Affinity DataIC50: 29nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532241(US11208422, Example 83 | US11208422, Example 82)
Affinity DataIC50: 30nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532226(US11208422, Example 68 | US11208422, Example 67)
Affinity DataIC50: 31nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532230(US11208422, Example 71)
Affinity DataIC50: 31nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532259(US11208422, Example 105 | US11208422, Example 104)
Affinity DataIC50: 31nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532254(US11208422, Example 99)
Affinity DataIC50: 34nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532162(US11208422, Example 14 | 3-{[2-(4-Chlorophenyl)imi...)
Affinity DataIC50: 35.1nMAssay Description:Xenopus laevis oocytes were selected as described elsewhere by way of illustration [Decher et al., FEBS Lett. 492, 84-89 (2001)]. Subsequently, the o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532257(US11208422, Example 103 | US11208422, Example 102)
Affinity DataIC50: 36nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532162(US11208422, Example 14 | 3-{[2-(4-Chlorophenyl)imi...)
Affinity DataIC50: 40.3nMAssay Description:Xenopus laevis oocytes were selected as described elsewhere by way of illustration [Decher et al., FEBS Lett. 492, 84-89 (2001)]. Subsequently, the o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532255(US11208422, Example 100)
Affinity DataIC50: 42nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532229(US11208422, Example 91 | US11208422, Example 90 | ...)
Affinity DataIC50: 43nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532189(US11208422, Example 31)
Affinity DataIC50: 47nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 188 total ) | Next | Last >>
Jump to: